Organization
NJ
25 abstracts
Abstract
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.Org: Children’s Hospital of Philadelphia, University of Pennsylvania, Children's Oncology Group Statistics and Data Center, University of Florida, CanSino Biologics, Dana Farber Cancer Institute, Boston, MA,
Abstract
Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).Org: Nashville, OneOncology, TN, South San Francisco, Genentech,
Abstract
Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.Org: Saint-Louis Hospital, APHP, University Paris Cité, Paris and Saint Cloud, France,
Abstract
Real-world tumor BRCA testing patterns and PARP inhibitor use in HER2-negative metastatic breast cancer.Org: Mayo Clinic, Rochester, MN, AstraZeneca, Gaithersburg, MD,
Abstract
Effect of real-time data-driven physician engagement on appropriate precision oncology testing.Org: Diaceutics, Parsippany, NJ, Utah Tech University, St. George's University of London,
Abstract
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.Org: University of California, San Diego Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Winship Cancer Institute of Emory University,
Abstract
Social vulnerability and clinical trial enrollment: The next frontier of health equity.Org: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Vizient Clinical Database Inc, New Brunswick, NJ, Irving,
Abstract
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.Org: University of Wisconsin, Carbone Cancer Center, Madison, WI, Wigen Biomedicine Technology (Shanghai), University of Wisconsin Carbone Cancer Center,
Abstract
Defining low-HER2 cancers using RNA quantification by next generation sequencing.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack Medical Center, NJ, Genomic Testing Cooperative, Irvine,
Abstract
NTRK positivity and conversion to appropriate personalized treatment.Org: Diaceutics, Parsippany, NJ, Utah Tech University, St. George Hospital,
Abstract
Validation of a digital pathology-based multimodal artificial intelligence model in oliogmetastatic castration-sensitive prostate cancer, including in patients from the STOMP and ORIOLE phase II randomized clinical trials.Org: Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD Anderson Cancer Center, New Brunswick, NJ,
Abstract
Optimizing patient (pt) care through pt-focused resources to prevent and manage hand-foot skin reaction (HFSR).Org: Bayer, Whippany, NJ, NJ, Sao Paulo (Brazil), Brazil,
Abstract
Secondary primary malignancy risk by ER, PR, and HER-2 status in post-menopausal women with breast cancer: A population-based analysis.Org: King Edward Medical University, Lahore Medical Research Center, Pakistan, King Edward Medical University Pakistan, Jhelum,
Abstract
Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation.Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Lake Erie College of Osteopathic Medicine,
Abstract
MRD assay to evaluate recurrence and response via a tumor-informed assessment: MARIA-Breast observational trial.Org: Invitae, San Francisco Department of Public Health, CanSino Biologics, Iselin, NJ,
Abstract
The Tempus TIME trial portal and clinical trial enrollment.Org: Memorial Care, Fountain Valley, CA, CanSino Biologics, OhioHealth, Columbus, OH,
Abstract
Treatment patterns and clinical outcomes following endocrine resistance among with HER2-low metastatic breast cancer: Retrospective observational study.Org: Daiichi Sankyo Inc., Basking Ridge, NJ, NJ, Cardinal Health, Dublin, Ireland,
Abstract
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine,
Abstract
Post-pandemic outlook of the oncology clinical trial landscape.Org: Kognitic, Somerset, NJ, New Jersey Cancer Care, Morristown Medical Center,
Abstract
Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy.Org: Janssen Scientific Affairs, Titusville, NJ, Horsham, PA, PainReform,
Abstract
Mechanism-based peripheral blood biomarkers to evaluate anticancer effects of the plinabulin/docetaxel combination (plin/doc) vs. doc alone in second/third line EGFR wild-type (WT) NSCLC.Org: Piedmont Cancer Institue, Atlanta Cancer Care, Galderma R&D, BeyondSpring Pharmaceuticals, Inc., NewYork-Presbyterian Brooklyn Methodist Hospital,
Abstract
In-hospital outcomes of patients with breast cancer and venous thromboembolism.Org: St Vincent Hospital, Worcester HIV Vaccine, MaaT Pharma, Brooklyn Hospital Program, Brooklyn ImmunoTherapeutics,
Abstract
Treatment patterns and outcomes among locally advanced cervical cancer patients receiving concurrent chemoradiotherapy.Org: ConcertAI, Cambridge University Hospitals NHS Foundation Trust, MaaT Pharma, Merck & Co., Inc., Rahway, NJ,
Abstract
Effect of TFF2-MSA on tumor growth and survival in anti-PD-1 treated MC38 and CT26.wt colorectal cancer models by targeting MDSCs.Org: Tonix Pharmaceuticals, Chatham, NJ, Southern Research Institute, Birmingham, AL,
Abstract
Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.Org: Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Analysis Group, Inc., Inc.,